Evidence map›Paper›PMID 34659510›Full record

ArticleExperimental and therapeutic medicine2021

LGR6 promotes glioblastoma malignancy and chemoresistance by activating the Akt signaling pathway.

Yuan Yuan Cheng, Xue Yang, Xin Gao, Si Xin Song, Ming Feng Yang, Fang Min Xie

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Native Endophytes ofFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yuan Yuan ChengDepartment of Oncology, Tai'an Central Hospital, Tai'an, Shandong 271000, P.R. China.
Xue YangDepartment of Oncology, Tai'an Central Hospital, Tai'an, Shandong 271000, P.R. China.
Xin GaoDepartment of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266100, P.R. China.
Si Xin SongDepartment of Neurosurgery, The Second Affiliated Hospital of Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, Shandong 270000, P.R. China.
Ming Feng YangInstitute of Basic Medicine of Shangdong, First Medical University and Shandong Academy of Medical Sciences, Tai'an, Shandong 270000, P.R. China.
Fang Min XieDepartment of Neurosurgery, The Second Affiliated Hospital of Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, Shandong 270000, P.R. China.
Shandong First Medical University · CNTaian City Central Hospital · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance is the primary cause of the poor outcome of glioblastoma multiforme (GBM) therapy. Leucine-rich repeat-containing G-protein coupled receptor 6 (LGR6) is involved in the growth and proliferation of several types of cancer, including gastric cancer and ovarian cancer. Therefore, the aim of the present study was to investigate the role of LGR6 in GBM malignancy and chemoresistance. Cell counting kit-8 and Matrigel

Indexed as

chemotherapyglioblastomaMK-2206temozolomide

Identifiers

PMID34659510
PMCPMC8515564
OpenAlexW3202988051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.